Ralfinamide

Ralfinamide
Clinical data
ATC code	None;
Identifiers
	IUPAC name N2-{4-[(2-Fluorobenzyl)oxy]benzyl}-L-alaninamide;
CAS Number	133865-88-0;
PubChem CID	5745207;
ChemSpider	4676525;
UNII	3LPF0S0GVV;
ChEMBL	ChEMBL2107771;
CompTox Dashboard (EPA)	DTXSID70158406 ;
ECHA InfoCard	100.120.272
Chemical and physical data
Formula	C17H19FN2O2
Molar mass	302.349 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2ccccc2F;
	InChI InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1; Key:BHJIBOFHEFDSAU-LBPRGKRZSA-N;

Ralfinamide (INN; development codes NW-1029, FCE-26742A, and PNU-0154339E) is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.

It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Na_v1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.

As of 2020, it was in phase III clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.

Clinical data

ATC code	None
Identifiers
IUPAC name N²-{4-[(2-Fluorobenzyl)oxy]benzyl}-L-alaninamide
CAS Number	133865-88-0
PubChem CID	5745207
ChemSpider	4676525
UNII	3LPF0S0GVV
ChEMBL	ChEMBL2107771
CompTox Dashboard (EPA)	DTXSID70158406
ECHA InfoCard	100.120.272
Chemical and physical data
Formula	C₁₇H₁₉FN₂O₂
Molar mass	302.349 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2ccccc2F
InChI InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1 Key:BHJIBOFHEFDSAU-LBPRGKRZSA-N